Bausch Health Companies vs Zoetis
BHC and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and ZTS compare
Zoetis is the larger company, worth 11 times as much as Bausch Health Companies ($34.5B against $3.2B).
Bausch Health Companies grew revenue faster over the last twelve months (10.8% versus 1.5% for Zoetis).
Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with −7.6% at Bausch Health Companies.
Zoetis pays a dividend yielding 1.9%; Bausch Health Companies does not pay one.
Zoetis scores higher on the StockData Score (17 against 8 for Bausch Health Companies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | ZTS |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $34.5B |
| Share price | $8.47 | $83.48 |
| Change, 1 year | 34.9% | −30.9% |
| Change, 5 years | −66.5% | −61.9% |
| Beta (5Y) | 0.90 | 0.06 |
| Employees | 20K | 15K |
| StockData Score | ||
| Total score | 8 | 17 (better) |
| Valuation score | 4 | 5 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 5 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | – | 13.7× |
| P/S | 0.3× (better) | 3.6× |
| P/B | – | 11.0× |
| EV/EBITDA | 9.3× (better) | 10.5× |
| P/FCF | 1.7× (better) | 14.9× |
| PEG | – | 1.34 |
| FCF yield | 58.8% (better) | 6.7% |
| Fair value | $35.68 | $154.11 |
| Margin of safety | 76.3% (better) | 45.8% |
| Growth | ||
| Revenue growth (TTM) | 10.8% (better) | 1.5% |
| Revenue growth, 5Y average | 5.0% | 7.2% (better) |
| Net income growth (TTM) | −332% | 0.96% (better) |
| EPS growth (TTM) | −336% | 5.6% (better) |
| EPS growth, 5Y average | – | 12.0% |
| Profitability | ||
| Gross margin | – | 71.5% |
| Operating margin | 11.2% | – |
| Net margin | −7.6% | 27.5% (better) |
| FCF margin | 16.8% | 24.3% (better) |
| Return on equity | – | 64.4% |
| Return on invested capital | 5.5% | – |
| Financial health | ||
| Debt / equity | – | 2.87 |
| Net debt / EBITDA | 7.57 | 1.85 (better) |
| Interest coverage | 0.8× | – |
| Current ratio | 1.56 | 3.08 (better) |
| Altman Z-score | 0.23 | 4.07 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.9% |
| Years of dividend growth | – | 13 |
| Dividend growth, 5Y average | – | 19.0% |
| Buyback yield | – | 10.6% |
| Shareholder yield | 0.00% | 12.5% (better) |
| Ownership | ||
| Held by institutions | 63.4% | 96.1% |
| Held by insiders | 31.5% | 0.08% |
| Insider net buying, 12 months | −$507K (better) | −$1.7M |
| Superinvestors holding | 1 | 3 (better) |
| Short interest, % of float | 2.9% | 4.1% |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- ZTS stock overview
- ZTS income statement
- ZTS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.